EP1863431A1 - Composition de soin des cheveux et/ou des cils contenant de l'aminexil associe a un agent activant la production de no, et utilisation de ladite composition - Google Patents

Composition de soin des cheveux et/ou des cils contenant de l'aminexil associe a un agent activant la production de no, et utilisation de ladite composition

Info

Publication number
EP1863431A1
EP1863431A1 EP06724223A EP06724223A EP1863431A1 EP 1863431 A1 EP1863431 A1 EP 1863431A1 EP 06724223 A EP06724223 A EP 06724223A EP 06724223 A EP06724223 A EP 06724223A EP 1863431 A1 EP1863431 A1 EP 1863431A1
Authority
EP
European Patent Office
Prior art keywords
hair
composition
agent
composition according
promoting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06724223A
Other languages
German (de)
English (en)
Inventor
Marie-Madeleine Cals-Grierson
Gilles Genain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0550710A external-priority patent/FR2883167B1/fr
Application filed by LOreal SA filed Critical LOreal SA
Publication of EP1863431A1 publication Critical patent/EP1863431A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43—Guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/88—Polyamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • Hair and/or eyelash care composition containing aminexil in combination with an agent for promoting the
  • the invention relates to a cosmetic or pharmaceutical composition containing the combination of 2, 4-diaminopyrimidine 3-N-oxide and of an agent for promoting the NO production, for inducing and/or stimulating the growth of human keratin fibres, and in particular of the hair and the eyelashes, and/or for stopping the loss thereof. It also relates to a cosmetic treatment process for stimulating the growth of these human keratin fibres and/or for stopping the loss thereof, and also to the use of the combination of 2, 4-diaminopyrimidine 3-N-oxide and of an agent for promoting the NO production, for inducing and/or stimulating hair or eyelash growth and/or for stopping loss thereof.
  • the human keratin fibres to which the invention applies are in particular head hair, the eyebrows, the eyelashes, beard hairs, moustache hairs and pubic hair. More especially, the invention applies to human head hair and/or eyelashes.
  • the invention relates to a physiologically acceptable composition which contains 2, 4-diaminopyrimidine 3-N-oxide and an agent for promoting the NO production for improving the condition of human hair, and in particular inducing agent for promoting the NO production for improving the condition of human hair, and in particular inducing and/or stimulating hair growth and/or stopping hair loss.
  • 2, 4-diaminopyrimidine 3-N-oxide is known under the name aminexil or 2,4-DPO.
  • the present invention relates more particularly to a physiologically acceptable and in particular cosmetic composition containing the combination of ⁇ NO-releasing" compounds in particular amino acids and more particulary arginine and its derivatives (polyarginine) , and/or of arginase inhibitors, with aminexil, this composition being intended to induce and/or stimulate hair growth and/or stop hair loss.
  • Hair growth and hair renewal are mainly determined by the activity of the hair follicles and of their matrix environment. Their activity is cyclical and comprises essentially three phases, namely the anagenic phase, the catagenic phase and the telogenic phase.
  • the anagenic phase (active phase or growth phase) , which lasts several years and during which the hair gets longer, is followed by a very short and transient catagenic phase which lasts a few weeks .
  • active phase or growth phase active phase or growth phase
  • transient catagenic phase which lasts a few weeks .
  • the hair undergoes a change, the follicle becomes atrophied and its dermal implantation appears higher and higher .
  • the terminal phase or telogenic phase which lasts a few months, corresponds to a resting phase of the follicle and the hair ends up by falling out. At the end of this resting period, a new follicle is generated in situ, and another cycle begins.
  • the head of hair is thus under permanent renewal and, out of the approximately 150 000 hairs that make up a head of hair, approximately 10% are at rest and will be replaced within a few months.
  • Hair growth and hair renewal are mainly determined by the activity of the hair follicles and of their matrix environment.
  • the head of hair is therefore undergoing permanent renewal, but by adulthood, the vascular system of the skin is fully developed and does not undergo any further modification except in the hair follicles, where it undergoes considerable variations at each hair cycle .
  • alopecia has not been explained, recent research has demonstrated the involvement of an autoimmunity imbalance.
  • Thl-type cytokines suggest the involvement of Thl-type cytokines in the appearance of alopecia.
  • a Th2-type profile could promote the repair of tissues damaged by Thl-type lymphocytes .
  • NO nitric oxide
  • CGRP calcium phosphate
  • angiogenesis the phenomenon of development of the microcirculation is called angiogenesis .
  • angiogenesis the phenomenon of development of the microcirculation.
  • the involution of this network and the disappearance of the capillaries of the dermal papilla go together with the change in phase and the passing into the catagenic phase.
  • the blood microcapillaries collapse and disappear.
  • the angiogenesis phenomenon observed during the anagenic phase depends on many trophic factors, on cytokines or on other biologically active molecules provided by the bloodstream or which are produced locally in particular by the fibroblasts of the dermal papilla or the bulbar keratinocytes .
  • trophic factors on cytokines or on other biologically active molecules provided by the bloodstream or which are produced locally in particular by the fibroblasts of the dermal papilla or the bulbar keratinocytes .
  • VEGF vascular endothelial growth factor
  • this factor contributes to maintaining a functional microvascularization around the hair follicle, and in particular around the base of the bulb and the dermal papilla, and also to providing nutrients necessary for correct hair growth.
  • the perifollicular microcirculation therefore plays an essential role in the hair growth process by providing the factors and the nutrients necessary for the growth of this follicle. Due to the essential role of the perifollicular microcirculation, any deficiency in the latter results in a decrease in the provision of the nutrient and gaseous (in particular oxygen) elements necessary for hair growth, leading to hair growth disorders and the gradual setting in of alopecia.
  • the natural loss or falling-out of the hair may be estimated, on average, as being a few hundred hairs per day for a normal physiological state. This process of permanent physical renewal undergoes a natural change during ageing, the hairs become finer and their cycles shorter.
  • hair loss may be greatly increased and the renewal cycles of the follicles may be greatly disturbed.
  • various causes may result in a substantial, temporary or permanent loss of hair. This may be loss and impairment of hair after pregnancy, during states of dietary malnutrition or imbalance, during physiological stress, or during states of asthenia or of hormonal dysfunction, as may be the case during or after the menopause. It may also be a case of loss or impairment of the hair related to seasonal phenomena .
  • alopecia which is essentially due to a disturbance in hair renewal, resulting, in a first stage, in acceleration of the frequency of the cycles to the detriment of the quality of the hair, and then of their quantity.
  • a gradual depletion of the head of hair then occurs and the hairs become gradually smaller, together with isolation of the bulbs due to a gradually increasing thickness of the perifollicular collagen matrix and of the outer connective sheath.
  • Revascularization is therefore made more difficult cycle after cycle.
  • the successive growth cycles result in hairs that become finer and shorter, gradually transforming into an unpigmented down. Certain areas are preferentially affected, especially the temporal or frontal lobes in men, and a diffuse alopecia of the crown of the head in women.
  • alopecia also covers an entire family of afflictions of the hair follicle whose final consequence is the permanent, partial or general loss of the hair. It is more particularly a matter of androgenic alopecia. In a large number of cases, early loss of hair occurs in genetically predisposed individuals; this is then androchronogenetic alopecia; this form of alopecia especially affects men. In general, any factor that results in an increase in blood supply to the hair follicle, either by activating angiogenesis or by opposing the regression thereof, or by acting on the rnicrovessels so as to limit their constriction, will have a beneficial effect on the energy supply required for correct growth of this same follicle.
  • compositions that make it possible to eliminate or reduce alopecia, and in particular to induce or stimulate hair growth or to decrease hair loss, have been sought for many years .
  • One of the pathways explored is precisely the maintenance of the vascularization around the hair follicle.
  • aminexil WO 96/09048 from L'Oreal
  • Lysyl hydroxylase and prolyl hydroxylase are enzymes involved in the formation of collagen fibres, and the deregulation of the functions thereof is one of the factors responsible for the development of perifollicular fibrosis.
  • Aminexil corresponds to the formula below:
  • the inventors have developed a novel physiologically acceptable composition containing the combination of aminexil with one or more agents for promoting the NO production.
  • This composition allows revascularization of the hair follicle, of its peripheral region and/or of the hair after each growth cycle, and also inhibition of the formation and of the taking hold of perifollicular fibrosis, a factor that worsens poor vascularization of the hair. It thus has a beneficial effect on the scalp, and in particular on hair growth, but also on certain hairs such as the eyelashes or the eyebrows and also on the nails.
  • the present invention thus relates to a composition for caring for and/or for treating keratin fibres, in particular human keratin fibres, such as the hair, and also for caring for and/or for treating the skin from which these fibres emerge, containing, in a physiologically acceptable medium, the combination of aminexil with at least one agent for promoting the NO production.
  • This composition is in particular intended to induce and/or stimulate the growth of keratin fibres and/or to stop the loss thereof and/or to increase the density thereof.
  • the expression "increase the density of keratin fibres, and in particular the hair density,” is intended to mean increasing the number of keratin fibres, in particular of hairs, per cm 2 of skin such as the scalp.
  • the invention also relates to the use of the combination of aminexil with at least one agent for promoting the NO production, as an agent for inducing and/or stimulating the growth of keratin fibres of human beings and/or for stopping the loss thereof and/or for increasing the density thereof.
  • the invention also relates to the cosmetic use of the combination of aminexil with at least one v agent for promoting the NO production, in a cosmetic composition for caring for and/or for making up keratin fibres of human beings, (as an agent) for reducing the loss of keratin fibres and/or for increasing the density thereof.
  • a subject of the invention is also the use of this combination, for preparing a composition for caring for and/or for treating keratin fibres of human beings, intended to induce and/or stimulate the growth of keratin fibres and/or to stop the loss thereof and/or to increase the density thereof.
  • the human keratin fibres to which the invention applies are in particular head hair, the eyebrows, the eyelashes, beard hairs, moustache hairs, pubic hairs and also the nails. More especially, the invention applies to human head hair and/or human eyelashes .
  • a subject of the invention is also the cosmetic use of the combination of aminexil with at least one agent for promoting the NO production, in a cosmetic hair care composition for human beings, as an agent for treating alopecia of natural origin, and in particular androgenic or androchronogenetic alopecia, and also the use of this combination for preparing a hair composition for human beings, intended to treat alopecia of natural origin, and in particular androgenic or androchronogenetic alopecia.
  • this composition makes it possible to maintain the head of hair in good condition and/or to combat natural hair loss, in particular in men.
  • a subject of the invention is also the cosmetic use of the combination of aminexil with at least one agent for promoting the NO production, in a cosmetic composition for caring for and/or for making up the eyelashes of human beings, for inducing and/or stimulating eyelash growth and/or for increasing the density thereof.
  • This composition thus makes it possible to maintain the eyelashes in good condition and/or to improve their condition and/or their appearance.
  • a subject of the invention is also the use of the combination of aminexil with at least one agent for promoting the NO production, for preparing a composition for caring for and/or for treating the eyelashes of human beings, intended to induce and/or stimulate eyelash growth and/or to increase the density thereof .
  • a subject of the invention is also the use of the combination of aminexil with at least one agent for promoting the NO production, for the manufacture of a composition for use in the treatment of disorders related to a reduction in the microcirculation or vascularization of the skin, and in particular of a hair follicle in human beings.
  • a subject of the present invention is also a cosmetic process for treating human keratin fibres and/or the skin from which these fibres emerge, such as the scalp, intended in particular to stimulate the growth of human keratin fibres such as the hair and the eyelashes of human beings, and/or to stop the loss thereof, characterized in that it consists in applying, to the human keratin fibres and/or the skin from which these fibres emerge, a cosmetic composition comprising the combination of aminexil with at least one agent for promoting the NO production, in leaving said composition in contact with these keratin fibres and/or said skin, and optionally in rinsing these keratin fibres and/or said skin.
  • This treatment process has the characteristics of a cosmetic process insofar as it makes it possible to improve the aesthetics of the keratin fibres, and in particular of the hair and of the eyelashes, by giving them greater vigour and an improved appearance. Furthermore, it may be used daily for several months, without a medical prescription.
  • a subject of the present invention is a cosmetic process for caring for human hair and/or the human scalp, with a view to improving their condition and/or their appearance, characterized in that it consists in applying, to the hair and/or the scalp, a cosmetic composition according to the invention comprising the combination of aminexil with at least one agent for promoting the NO production, in leaving said composition in contact with the hair and/or the scalp, and optionally in rinsing the hair and/or the scalp .
  • This process thus allows care of the human scalp and of human hair, and in particular an anti-hair loss/hair regrowth action, but also an antimicrobial action and, ultimately, an anti-dandruff action, an action promoting healing of the scalp, and an action against human hair becoming greasy.
  • a subject of the invention is also the cosmetic use of the combination of aminexil with at least one agent for promoting the NO production, in a cosmetic hair composition, as a scalp care agent, and in particular as an agent with an anti-dandruff action on the scalp, and/or a healing action on the scalp and/or an action against human hair becoming greasy.
  • a subject of the invention is also the use of the combination of aminexil with at least one agent for promoting the NO production, for manufacturing a composition intended to treat and/or limit the formation of dandruff on the scalp and/or to heal the scalp and/or to treat and/or to limit the formation of grease on human hair.
  • a subject of the invention is also a cosmetic process for caring for and/or for making up human eyelashes, with a view to improving their condition and/or their appearance, characterized in that it consists in applying, to the eyelashes, a mascara composition comprising the combination of aminexil with at least one v agent for promoting the NO production and in leaving said composition in contact with the eyelashes.
  • This mascara composition can be applied alone or as an undercoat for a conventional pigmented mascara, and can be removed like a conventional pigmented mascara, with a conventional makeup-removing cream or lotion.
  • the term "at least one" signifies one or more (2, 3 or more) .
  • the composition may contain one or more vasodilators or one or more natural amino acids or one or more arginase inhibitors or a mixture of these compounds .
  • composition according to the invention contains 2, 4-diaminopyrimidine 3-N-oxide.
  • This compound is soluble in water and in a water/alcohol mixture in any proportion. It may be chosen in sufficient amount to obtain, in combination with one or more complementary compounds active on the regrowth of keratin fibres, in particular human keratin fibres, and/or on stopping the loss thereof, an increase in the density of keratin fibres, in particular human keratin fibres, and/or a reduction in the loss thereof, and in particular an increase in the density of human hair and/or a reduction in the loss thereof.
  • aminexil can be used, for topical application to the human scalp and human hair, in an amount representing from 10 ⁇ 3 % to 5% of the total weight of the composition, and preferably in an amount representing from 10 ⁇ 2 % to 2% of the total weight of the composition, for example from 0.5% to 2%.
  • composition according to the invention also contains one or more complementary compounds active on the regrowth of keratin fibres and/or on stopping the loss thereof, chosen from vasodilators, natural amino acids and arginase inhibitors, and mixtures thereof. Furthermore, some of these complementary compounds may be both vasodilator compounds and natural amino acids. Preferably, the active complementary compound is both a vasodilator compound and an amino acid.
  • the agents for promoting the NO production are preferably chosen from:
  • NOS Nitric Oxide Synthase
  • the agents that modulate NO synthesis can act directly on the chemical release of NO, or on the enzymatic release of NO by means of the enzyme for NO synthesis, NO-Synthase or NOS (its various isoforms) .
  • They may also be elements that ultimately regulate the NO concentration at the cellular level, by acting on the mechanisms of protein synthesis for the enzyme, on the stability and/or the activity of the enzyme and also on the stimulation of its synthesis, on the stability of the NOS mRNA, and/or on the stability of the released NO.
  • NO-synthase covers a family of enzymes that provide the enzymatic catalysis of
  • NO-synthases exist in three forms, two constitutive forms, which nomenclature includes neuronal NO-synthase (or NOS 1) and endothelial NO-synthase (or NOS 3) , and the inducible form (or NOS 2) (Medecine/Sciences, 1992, 8, pp. 843-845) .
  • the NOS activity stimulators agents for promoting can also acton the distrity of a NO precursor and, in particular in the case of L-arginine, they can be selected from arginase inhibitors. Inhibiting the arginases allows to increase the disponibiity of arginine and to increase the synthesis of NO.
  • NOS synthesis and/or activity stimulators mention may, for example, be made of arachidonic acid, bradykinin, L-glutamic acid, histamine, hydroxyguanidine, interleukin-l ⁇ , interleukin-l ⁇ , interleukin-2, lipopolysaccharides, tetrahydro-L-biopterin and TNF- ⁇ . Mention may also be made of L-2-pyrrolidone-5-carboxylic acid and its derivatives, as described in application EP 1 226 822.
  • arginase inhibitors that can be used in the composition of the invention, mention may be made of: N-omega-hydroxy-nor-L-arginine (nor-NOHA) , aminoboronohexanoic acid (ABH), S-(+)-amino- 5-iodoacetamidopentanoic acid, difluoromethylornithine (DFMO), L-norvaline and S- (2-boronoethyl) -L-cysteine .
  • nor-NOHA aminoboronohexanoic acid
  • DFMO difluoromethylornithine
  • L-norvaline L-norvaline
  • S- (2-boronoethyl) -L-cysteine S- (2-boronoethyl) -L-cysteine
  • nonpolymeric NO-releasing agents i.e. any NO- releasing agent that is peptide or nonpeptide in nature, i.e. any NO-releasing agent that is peptide or nonpeptide in nature, it being understood that, when the agent is peptide in nature, it comprises from 1 to 5 amino acids, preferably from 2 to 4 amino acids.
  • the NO-releasing vasodilator compounds may be chemical precursors of NO (subsequently referred to as NO donors) , or may be metabolized and bring about the release of NO via oxidoreduction processes.
  • the NO-releasing vasodilator agents may also generate NO by photoactivation. The release of NO by these compounds can be verified by assaying the byproducts of NO (nitrates and nitrites) released into a liquid medium or by directly measuring the NO gas released on the skin.
  • the NO-releasing agents that can be used in the invention which are metabolized to give NO, can be chosen from amino acids, peptides, the proanthocyanidins as described in application JP 2001- 278792, and the cyclic terpenes described in patent application WO 00/044368.
  • vasodilator amino acids that can be used in the invention, which stimulate NO release by enzymatic action, mention may be made of L-arginine, histidine, lysine, ornithine, glutamic acid, aspartic acid, serine, glycine, cysteine and threonine.
  • Basic, acidic or alcoholic aliphatic amino acids are preferred.
  • the NO-releasing peptides that can be used in the invention may comprise from 2 to 30 amino acids, for example from 5 to 20 amino acids, and better still from 5 to 15 amino acids. These peptides comprise amino acids such as those described above.
  • these NO-releasing peptides mention may be made of: - L-arginine oligomers (called polyarginine) , oligomers of an L-arginine analogue or of one of their derivatives, such as those described by Exsymol in application EP 1 060 739 and by Essentia in application WO 03/072039, - histidine- and/or alanine-based peptides as described by KS Biomedix Ltd in application WO 02/04005, in particular histidine dipeptides such as carnosine, anserine and homocarnosine .
  • Arginine oligomers that are preferred according to the invention comprise from 7 to 15 L-arginine units, for example 7, 9, 11, 13 or 15 L-arginine units.
  • the arginine oligomer consists only of arginine.
  • it may be included in a peptide or polymer that is slightly larger in size and that contains other amino acids (for example, glycine) ; in particular, the arginine oligomer is located at either the C-terminal or N-terminal end of the polymer or of the peptide.
  • An example of such a peptide is gly 3 -arg 7 .
  • the NO donor vasodilator compounds that can be used in the invention can also be chosen from organic compounds which give up NO by chemical reaction, comprising a nitro (-NO2) or nitroso (-NO) substituent, oximes, heterocyclic NO donors, compounds that give nitroxyl, hydroxylamine, nonoate compounds (-N(NO)O " ), N-hydroxyguanidine and its salts (such as N-hydroxyguanidine acetate and hydroxyguanidine hemisulphate) , inorganic NO donors, nitrosyl transition metals, nitrosodiphenylamine derivatives, the cyclosine from the Thissen laboratories, SMP-5185 or N-nitratopivaloyl-S- (N' -acetylalanyl) cysteine ethyl ester from the Schwarz Pharma laboratories, photolabile NO donors, guanylate cyclase activators and/or cGMP stimulators, and molecules developed by the company Nicox, such as NO
  • NO donors examples include organic esters of nitric acid, such as ethylene glycol dinitrate, isopropyl nitrate, glyceryl 1-mononitrate, glyceryl 1, 2-dinitrate, glyceryl 1, 3-dinitrate, butane-1, 2, 4-triol trinitrate, erythrityl tetranitrate or pentaerythrityl tetranitrate.
  • organic esters of nitric acid such as ethylene glycol dinitrate, isopropyl nitrate, glyceryl 1-mononitrate, glyceryl 1, 2-dinitrate, glyceryl 1, 3-dinitrate, butane-1, 2, 4-triol trinitrate, erythrityl tetranitrate or pentaerythrityl tetranitrate.
  • - compounds comprising a nitro or nitroso substituent linked to a carbon atom (C-nitro, C- nitroso) , such as 2-methyl-2-nitrosopropane, ethylene glycol dinitrate, glyceryl 1-mononitrate, glyceryl 1, 2-dinitrate, glyceryl 1, 3-dinitrate, butane-1, 2, 4- triol trinitrate, erythrityl tetranitrate or pentaerythrityl tetranitrate, and organic nitrites such as ethyl nitrite, isobutyl nitrite or isopentyl nitrite (amyl nitrite) ;
  • S-nitro, S-nitroso compounds comprising a nitro or nitroso substituent linked to a sulphur atom
  • S-nitro, S-nitroso such as S-nitroso-N-acetylpenicillamine (SNAP) , S-nitrosoglutathione (GSNO) , N-acetyl-S- nitrosopenicillaminyl-S-nitrosopenicillamine, S-nitrosocysteine, thionitrates or thionitrites (S-nitrosothiols) ;
  • - compounds comprising a nitro or nitroso substituent linked to an oxygen atom (0-nitroso) , for instance glyceryl trinitrate (GTN) or nitroglycerine, is ⁇ sorbide dinitrate (ISDN) , isosorbide 5-mononitrate (IS-5-N) , isopropyl nitrate, isobutyl nitrate, isopentyl nitrate, ethylene glycol dinitrate, glyceryl 1-mononitrate, glyceryl 1, 2-dinitrate, glyceryl 1, 3-dinitrate, butane-1, 2, 4-triol trinitrate, erythrityl tetranitrate, pentaerythrityl tetranitrate, and organic nitrites such as ethyl nitrite, isobutyl nitrite or isopentyl nitrite (amyl nitrite) ;
  • GTN glyceryl
  • N-nitroso compounds comprising a nitro or nitroso substituent linked to a nitrogen atom
  • N-nitroso such as Z ⁇ 7-nitrosodimethylamine (NDMA) , N-methyl-IV- nitrosourea (NMU), 1, 3-bis (2-chloroethyl) -1-nitrosourea (BCNU) , l-methyl-3-nitro-l-nitrosoguanidine (MNNG) , streptozotocine (STZ) , ⁇ 7-nitroso-.W-phenylhydroxylamine, N-nitrosamines, N-hydroxy-N-nitrosamines, N-nitrosamides, N-nitrosoguanidines, N-nitrosohydrazines or N-nitrosimines .
  • NDMA Z ⁇ 7-nitrosodimethylamine
  • NMU N-methyl-IV- nitrosourea
  • BCNU 1, 3-bis (2-chloroethyl) -1-nitros
  • the NO donors that can be used in the invention can also be chosen from nonoate compounds such as spermine nonoate (Sper/NO) , diethylamine nonoate (DEA/NO) , diethylenetriamine nonoate (DETA nonoate), A ⁇ W-bismethyl-l, 6-hexenediamine (MAMA/NO), N-propyl-1, 3-propanediamine (PAPA/NO), iV-isopropyl- 1, 3-propanediamine, WVN'-bismethyl-l, 3-propanediamine, W / N'-bisethylethylenediamine, l- ⁇ [4' ,5' -bis (carboxymethoxy) -2' -nitrophenyl]methoxy ⁇ - 2-oxo-3, 3-diethyl-l-triazine or
  • nonoate compounds such as spermine nonoate (Sper/NO) , diethylamine nonoate (DEA/NO) , diethylenetriamine nonoate (D
  • NO donors of the oxime chemical family that can be used in the invention are, for example: - (+)-[ (E)-ethyl-2-[ (E) -hydroxyimino] -
  • the NO donors that can be used in the invention can also be chosen from heterocyclic compounds such as :
  • sydnonimines such as molsidomine (MOL) , 3-morpholinosydnonimine (linsidomine, SIN-I) , the W-morpholino-M-nitrosaminoacetonitrile/ ⁇ -cyclodextrin (SIN-lA/gamma CD) complex,
  • oxatriazoles such as [1, 2, 3, 4-oxatriazolium- 5-amino-3- (3, 4-dichlorophenyl) ] chloride (GEA 3162), [1, 2, 3, 4-oxatriazolium-5-amino-
  • the NO donors that can be used in the invention can also be chosen from compounds carrying a nitroxyl (-NO " ) substituent, such as benzenesulphohydroxamic acid (Piloty's acid, PA, BSHA), N-acetyl-N-acetoxy-4-chlorobenzenesulphonamide, cyanamide, sodium trioxodinitrate (Angeli's salt) and sodium nitroxyl.
  • a nitroxyl such as benzenesulphohydroxamic acid (Piloty's acid, PA, BSHA), N-acetyl-N-acetoxy-4-chlorobenzenesulphonamide, cyanamide, sodium trioxodinitrate (Angeli's salt) and sodium nitroxyl.
  • the NO donors that can be used in the invention can also be chosen from inorganic compounds such as nitrosonium salts, nitrosyl halides, nitrite salts, sodium nitrite (NaN ⁇ 2) , nitrosyl hydrogen sulphate (NOHSO 4 ) , nitrosyl chloride (NOCl) , nitrosyl tetrafluoroborate (NOBF 4 ) , peroxynitrite (ONOO " ) and sodium azide (NaNs) .
  • inorganic nitrites associated with organic acids such as ascorbic acid or salicylic acid, as described in application WO 99/44622.
  • the NO donors that can be used in the invention can also be chosen from transition metal complexes with nitrosyl (-NO + ) as ligand, dinitrosyl- Iron(II) complexes, complexes of nitrosyl with iron- sulphur clusters, complexes of nitrosyl with other transition metals, sodium nitroprusside Na2 [Fe (CN) 5 N0] , the dinitrosyl-iron-cysteine (1:20) (DNIC) complex and pentachloronitrosylruthenium (K2 [Ru (NO) CI 5 ] ) .
  • photolabile NO donors mention may in particular be made of the compounds :
  • the agent for promoting the NO production when in molecular form, it can be adsorbed onto or encapsulated in particulate structures having a size that can range from 1 nm to a few ⁇ m, for instance microcapsules, microparticles, vesicular dispersions of ionic type (liposomes or oleosomes) and/or nonionic type (niosomes) and/or dispersions of nanospheres.
  • These particles can be advantageously porous and can consist of silicates or of aluminosilicates .
  • Examples of such formulations are described in particular in documents EP 199 636, EP 375 520, EP 447 318, EP 557 489, WO 97/12602, EP 1 151 741 or US 5 914 126.
  • microspheres may be prepared according to the method described in patent application EP 0 375 520.
  • the nanospheres may be in the form of an aqueous suspension and may be prepared according to the methods described in patent applications FR 0015686 and FR 0101438.
  • Oleosomes consist of an oil-in-water emulsion formed by oily globules provided with a lamellar liquid crystal coating dispersed in an aqueous phase (see patent applications EP 0 641 557 and EP 0 705 593) .
  • the agent for promoting the NO production of the composition according to the invention can also be encapsulated in nanocapsules consisting of a lamellar coating obtained from a silicone surfactant as described in document EP 0 780 115; the nanocapsules can also be prepared based on water-dispersible sulphonic polyesters according, for example, to the technique described in patent application FR 0113337.
  • the agent for promoting the NO production is chosen from NO-releasing compounds and NO itself.
  • the NO-releasing compounds are chosen from nitroglycerine, S-nitroso-N-acetylpenicillamine (SNAP) , diethylenetriamine nonoate (DETA nonoate) , S-nitrosothiols and SNAGs (nitrosated thiosugars) , sinitrodil, N,N-dimethylhexanediamine (DHMD/NO) , isosorbide dinitrate (ISDN) , trinitrine (GTN) , isosorbide 5-mononitrate (IS5N) and amino acids.
  • the agent for promoting the NO production is selected from the aamino acids and particularily selected from arginine, lysine or an oligomer of arginine or of lysine.
  • amino acids can be chosen from basic amino acids such as arginine, lysine or histidine and nonpolar natural amino acids such as glycine, alanine, valine, leucine or isoleucine.
  • amino acid used is arginine or lysine, or a mixture thereof.
  • the amino acids are in the form of a monomer an oligomer containing from 2 to 30 amino acids, preferably from 5 to 20 amino acids, and better still from 5 to 15 amino acids. It may be in the form of a homooligomer or of an oligomer of several different amino acids (2 or 3) .
  • the agents for promoting the NO production can be used, in combination with the aminexil, alone or as a mixture, in an amount ranging from 10 ⁇ 2 % to 10% of the total weight of the composition, and preferably in an amount representing from 10 ⁇ 2 % to 5% of the total weight of the composition, for example from 0.5% to 2%.
  • the composition of the invention may be for cosmetic or pharmaceutical use.
  • the composition of the invention is for cosmetic use.
  • the composition must contain a nontoxic physiologically- acceptable medium that can be applied to the skin, including the scalp and the eyelids, and the integuments such as human keratin fibres.
  • the term "cosmetic" is intended to mean a composition with a pleasant appearance, odour and feel.
  • the composition according to the invention can be ingested or applied to the skin or the keratin fibres (to any cutaneous region or fibres to be treated) . It can also be injected.
  • the vasodilator is advantageously an amino acid, and in particular arginine or polyarginine.
  • the agent (s) for p A romoting the NO production can be used orally in an amount of from 0.1 to 300 mg per day, 5 to 10 mg/d.
  • a preferred composition of the invention is a composition for cosmetic use and in particular for topical application to the skin and the keratin fibres, and more especially to the scalp, the hair, the nails and the eyelashes.
  • This composition may be in any of the known pharmaceutical forms suitable for the method of use.
  • the composition may be in the form of an aqueous, alcoholic, aqueous-alcoholic or oily solution or suspension, of an emulsion or dispersion of more or less fluid, and in particular liquid or semi- liquid, consistency, obtained by dispersion of a fatty- phase in an aqueous phase (0/W) or conversely (W/0) , of a solid dispersion or emulsion (0/W) or (W/0) , of a more or less fluid or solid aqueous, aqueous-alcoholic or oily gel, of a loose or compacted powder to be used as it is or to be incorporated into a physiologically acceptable medium, or else of microcapsules or microparticles, or of vesicular dispersions of ionic and/or nonionic type.
  • a composition in the form of a foam or else in the form of a spray or of an aerosol, then comprising a pressurized propellant, can also be envisaged.
  • composition may thus be in the form of a lotion, serum, milk, 0/W or W/0 cream, gel, salve, ointment, powder, balm, patch, impregnated pad, soap, cake or foam.
  • the composition for application to the scalp or the hair may be in the form of a haircare lotion, for example to be applied daily or twice-weekly, of a shampoo or a hair conditioner, in particular to be applied twice-weekly or weekly, of a liquid or solid scalp cleansing soap to be applied daily, of a hairstyle shaping product (lacquer, hair setting product or styling gel) , of a treatment mask, or of a foaming gel or cream for cleansing the hair. It may also be in the form of a hair dye or mascara to be applied with a brush or a comb.
  • the composition to which the invention applies may be in the form of a pigmented or unpigmented mascara, to be applied with a brush to the eyelashes or alternatively to beard or moustache hair.
  • the composition may be in the form of an aqueous lotion or an oily suspension, for example in the form of serum.
  • the composition may be in the form of capsules, of granules, of oral syrups or of tablets.
  • the composition according to the invention is in the form of a hair cream or hair lotion, of a shampoo or a conditioner for the hair, or of a mascara for the hair or the eyelashes.
  • compositions according to the invention are those generally used in the fields under consideration. Furthermore, these compositions are prepared according to the usual methods.
  • the proportion of the fatty phase may range from 2% to 80% by weight, and preferably from 5% to 50% by weight, relative to the total weight of the composition.
  • the aqueous phase is adjusted as a function of the content of fatty phase and of compound (s) (A) and also of that of the optional additional ingredients, so as to obtain 100% by weight. In practice, the aqueous phase represents from 5% to 99.9% by weight.
  • the fatty phase may contain fatty or oily compounds that are liquid at ambient temperature (25°C) and atmospheric pressure (760 mmHg) , which are generally known as oils. These oils may be compatible or incompatible with one another and may form a macroscopically homogeneous liquid fatty phase or a two-phase or three-phase system. In addition to the oils, the fatty phase may contain waxes, gums, lipophilic polymers or "pasty" or viscous products containing solid parts and liquid parts .
  • the aqueous phase contains water and, optionally, an ingredient that is miscible in any proportion with water, for instance Ci to C 8 lower alcohols such as ethanol or isopropanol, polyols, for instance propylene glycol, glycerol or sorbitol, or alternatively acetone or ether.
  • Ci to C 8 lower alcohols such as ethanol or isopropanol
  • polyols for instance propylene glycol, glycerol or sorbitol, or alternatively acetone or ether.
  • the emulsifiers and co-emulsifiers used for obtaining a composition in the form of an emulsion are those generally used in the cosmetics and pharmaceutical fields. Their nature also depends on the sense of the emulsion.
  • the emulsifier and, optionally, the co-emulsifier are present, in the composition, in a proportion ranging from 0.1% to 30% by weight, preferably from 0.5 to 20% by weight, and better still from 1 to 8%.
  • the emulsion may also contain lipid vesicles, and especially liposomes.
  • the fatty phase may represent more than 90% of the total weight of the composition.
  • the composition is an aqueous, alcoholic or aqueous-alcoholic solution or suspension, and better still a water/ethanol solution or suspension.
  • the alcoholic fraction may represent from 5% to 99.9%, and better still from 8% to 80%.
  • the composition is a wax-in-water or wax-in-oil dispersion, a gelled oil or an aqueous gel, which may be pigmented or unpigmented. Additional features of the invention
  • composition of the invention may also comprise other ingredients normally used in the fields concerned, chosen from solvents, aqueous-phase or oily- phase thickeners or gelling agents, dyestuffs that are soluble in the medium of the composition, solid particles of the filler or pigment type, antioxidants, preserving agents, fragrances, electrolytes, neutralizers, UV blockers, for instance sunscreens, film-forming polymers, cosmetic and pharmaceutical active agents with a beneficial effect on the skin or integuments, and in particular keratin fibres (such as vitamins), and mixtures thereof.
  • other ingredients normally used in the fields concerned chosen from solvents, aqueous-phase or oily- phase thickeners or gelling agents, dyestuffs that are soluble in the medium of the composition, solid particles of the filler or pigment type, antioxidants, preserving agents, fragrances, electrolytes, neutralizers, UV blockers, for instance sunscreens, film-forming polymers, cosmetic and pharmaceutical active agents with a beneficial effect on the skin or integuments, and in particular ker
  • additives may be present in the composition according to the amounts generally used in the cosmetics and dermatological field, and in particular in a proportion of from 0.01 to 50% of the total weight of the composition, and better still from 0.1 to 20%, and for example from 0.1 to 10%.
  • these adjuvants may ⁇ be introduced into the fatty phase, into the aqueous phase and/or into the lipid vesicles, and especially liposomes .
  • those skilled in the art will take care to select the optional complementary additives and/or the amount thereof in such a way that the advantageous properties of the composition according to the invention, in particular namely the increase in the density of keratin fibres, are not, or are not substantially, impaired by the envisaged addition.
  • oils that can be used in the invention mention may be made of oils of mineral origin (liquid petroleum jelly, hydrogenated isoparaffin) , oils of plant origin (liquid fraction of shea butter, sunflower oil, apricot oil, soybean oil, fatty alcohol or fatty acid) , oils of animal origin (perhydrosqualene) , synthetic oils (fatty acid esters, purcellin oil) , silicone oils (linear or cyclic polydimethylsiloxanes, phenyl trimethicones) and fluoro oils (perfluoropolyethers) .
  • oils of mineral origin liquid petroleum jelly, hydrogenated isoparaffin
  • oils of plant origin liquid fraction of shea butter, sunflower oil, apricot oil, soybean oil, fatty alcohol or fatty acid
  • oils of animal origin perhydrosqualene
  • synthetic oils fatty acid esters, purcellin oil
  • silicone oils linear or cyclic polydimethylsiloxanes, phenyl trimethicones
  • fluoro oils perfluoro
  • emulsifiers that can be used in the invention, mention may, for example, be made of glyceryl stearate, glyceryl laurate, sorbitol stearates, sorbitol oleates, alkyl dimethicone copolyols (with alkyl ⁇ 8) and mixtures thereof for a W/0 emulsion.
  • Polyethylene glycol monostearate or monolaurate, polyoxyethylenated sorbitol stearate or oleate, and dimethicone copolyols, and mixtures thereof can also be used for an 0/W emulsion.
  • hydrophilic gelling agents that can be used in the invention, mention may be made of carboxyvinyl polymers (carbomer) , acrylic copolymers such as acrylate/alkyl acrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropyl cellulose, natural gums and clays, and as lipophilic gelling agents, mention may be made of modified clays, for instance bentones, metal salts of fatty acids, for instance aluminium stearates, hydrophobic-treated silica and ethylcellulose, and mixtures thereof.
  • the composition may contain an additional active agent other than those mentioned above, which may be hydrophilic and chosen from proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, plant extracts (those from Iridacea plants or from soybean) and hydroxy acids (fruit acid, salicylic acid) ; or lipophilic and chosen from retinol (vitamin A) and its derivatives, especially an ester (retinyl palmitate) , tocopherol (vitamin E) and its derivatives, especially an ester (tocopheryl acetate or palmitate) , essential fatty acids, ceramides, essential oils, salicylic acid derivatives, for instance 5-n-octanoylsalicylic acid, hydroxy acid esters, and phospholipids, for instance lecithin, and mixtures thereof .
  • an additional active agent other than those mentioned above, which may be hydrophilic and chosen from proteins or protein hydrolysates, amino acids,
  • additional compound that promotes hair regrowth and/or limits hair loss.
  • additional compounds are in particular chosen from the lipoxygenase inhibitors as described in EP 0648488, the bradykinin inhibitors described in particular in EP 0845700, anti-androgenic agents, cyclosporines and analogues thereof, antimicrobial agents and antifungal agents, anti-inflammatories and retinoids, alone or as a mixture .
  • the anti-androgenic agents that can be used include in particular steroidal or non-steroidal inhibitors of 5 ⁇ -reductase, such as finasteride and the compounds described in US 5 516 779, cyprosterone acetate, azelaic acid, its salts and its derivatives and the compounds described in US 5 480 913, flutamide, the compounds described in US patents 5 411 981, 5 565 467 and 4 910 226, and also oxendolone, spironolactone, diethylstilbestrol and flutamide.
  • 5 ⁇ -reductase such as finasteride and the compounds described in US 5 516 779, cyprosterone acetate, azelaic acid, its salts and its derivatives and the compounds described in US 5 480 913, flutamide, the compounds described in US patents 5 411 981, 5 565 467 and 4 910 226, and also oxendolone, spironolac
  • the antimicrobial or antifungal compounds can be chosen from selenium derivatives, ketoconazole, octopirox, triclocarban, triclosan, zinc pyrithione, itraconazole, metronidazole, crotamiton or pyrethrinoids, asiatic acid, hinokitiol, mipirocine, tetracyclines, especially erythromycin and the compounds described in EP 0680745, clinycin hydrochloride, benzoyl peroxide or benzyl peroxide, minocycline and compounds belonging to the imidazole class, such as econazole, ketoconazole or miconazole or salts thereof, nicotinic acid esters, including especially tocopheryl nicotinate, benzyl nicotinate and C x -C 6 alkyl nicotinates, for instance methyl nicotinate or hexyl nicotinate.
  • the anti-inflammatories can be chosen from steroidal anti-inflammatories, for instance glucocorticoids, corticosteroids (for example: hydrocortisone) , and non-steroidal anti-inflammatories, for instance glycyrrhetinic acid and ⁇ -bisabolol, benzydamine, and the compounds described in EP 0770399, WO 94/06434 and FR 2268523.
  • steroidal anti-inflammatories for instance glucocorticoids, corticosteroids (for example: hydrocortisone)
  • non-steroidal anti-inflammatories for instance glycyrrhetinic acid and ⁇ -bisabolol, benzydamine
  • the retinoids may be chosen from retinoic acid, isotretinoin, acitretin and tazarotene.
  • compositions for topical application comprising aminexil and/or a vasodilator and/or an amino acid and/or an arginase inhibitor, to be encapsulated and in particular in liposomal form, as in particular described in document WO 94/22468.
  • the compound encapsulated in the liposomes can be delivered selectively to the hair follicle .
  • the composition according to the invention may be applied to the alopecia-affected areas of the scalp and the hair of an individual, and optionally left in contact for several hours and optionally rinsed off.
  • the composition may, for example, be applied in the evening, kept in contact throughout the night and optionally shampooed out in the morning. These applications can be repeated daily for one or more months according to the individual .
  • This lotion is applied to the scalp once or twice a day, in a proportion of 1 ml per application, by lightly massaging the scalp so as to cause the active agent to penetrate. The head of hair is subsequently dried in the open air. This lotion makes it possible to decrease hair loss and to promote regrowth thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne une composition d'application topique destinée à l'entretien et/ou à la fabrication de fibres de kératine humaine, dans un support physiologiquement acceptable associant l'aminexil à au moins un agent qui active la production de NO. Cette composition induit et/ou stimule la croissance de fibres de kératine, telles que les cheveux et les cils, et/ou freine leur chute et/ou augmente leur densité.
EP06724223A 2005-03-18 2006-02-27 Composition de soin des cheveux et/ou des cils contenant de l'aminexil associe a un agent activant la production de no, et utilisation de ladite composition Withdrawn EP1863431A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0550710A FR2883167B1 (fr) 2005-03-18 2005-03-18 Composition de soin capillaire et/ou des cils contenant de l'aminexil en association avec un vasodilatateur, destinee a stimuler la croissance des cheveux et/ou des cils et/ou freiner leur chute, ses utilisations
US68421905P 2005-05-25 2005-05-25
PCT/EP2006/003295 WO2006097359A1 (fr) 2005-03-18 2006-02-27 Composition de soin des cheveux et/ou des cils contenant de l'aminexil associe a un agent activant la production de no, et utilisation de ladite composition

Publications (1)

Publication Number Publication Date
EP1863431A1 true EP1863431A1 (fr) 2007-12-12

Family

ID=36754590

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06724223A Withdrawn EP1863431A1 (fr) 2005-03-18 2006-02-27 Composition de soin des cheveux et/ou des cils contenant de l'aminexil associe a un agent activant la production de no, et utilisation de ladite composition

Country Status (2)

Country Link
EP (1) EP1863431A1 (fr)
WO (1) WO2006097359A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009127248A1 (fr) * 2008-04-16 2009-10-22 United Technologies Ut Ag Compositions cosmétiques et dermatologiques contenant de l'interleukine-1 alpha
EA023680B1 (ru) * 2009-03-17 2016-06-30 Общество С Ограниченной Ответственностью "Сенгара" Интерлейкин-1 бета в косметических композициях и способы его использования
WO2012091757A1 (fr) * 2010-12-31 2012-07-05 Corridor Pharmaceuticals, Inc. Inhibiteurs de l'arginase et leurs procédés d'utilisation
FR2973234A1 (fr) * 2011-03-31 2012-10-05 Oreal Utilisation cosmetique d'inhibiteur d'arginase, comme agent pour freiner la chute des cheveux, des sourcils et/ou des cils
US20150313956A1 (en) * 2014-05-05 2015-11-05 Napier Consulting Llc Compositions and methods for hair growth
US10603266B2 (en) 2014-10-09 2020-03-31 Mediproduce, Inc. Eyelash cleaning agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU87766A1 (fr) * 1990-07-20 1992-03-11 Oreal Utilisation de derives de pyrimidine 3-oxyde pour freiner la chute des cheveux et compositions topiques mises en oeuvre
ES2340450T3 (es) * 1997-09-17 2010-06-02 STRATEGIC SCIENCE & TECHNOLOGIES, LLC Un suministro de arginina para el calentamiento de tejidos frios/enfriados.
JP4229842B2 (ja) * 2002-02-22 2009-02-25 ルバンス セラピュティックス インク． Ｌ−アルギニンオリゴマーを含む化粧品処方
FR2854630B1 (fr) * 2003-05-06 2005-06-10 Oreal Composition capilaire contenant un derive de pyrimidine n-oxydase, son utilisation pour stimuler la pousse des fibres keratiniques et/ou freiner leur chute

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006097359A1 *

Also Published As

Publication number Publication date
WO2006097359A1 (fr) 2006-09-21

Similar Documents

Publication Publication Date Title
US20090215837A1 (en) Administration of pyridinedicarboxylic acid compounds for stimulating or inducing the growth of human keratinous fibers and/or arresting their loss
JP2003300841A (ja) ヒトのケラチン繊維の成長を刺激又は誘発し及び／又はその喪失を遅延させるためのピリジンジカルボン酸誘導体又はその塩の一つの用途
WO2006097359A1 (fr) Composition de soin des cheveux et/ou des cils contenant de l'aminexil associe a un agent activant la production de no, et utilisation de ladite composition
FR2939030A1 (fr) Utilisation de la taurine pour le traitement de la canitie
US20040242665A1 (en) Hair composition containing a styrylpyrazole compound, and use thereof for stimulating or inducing hair or eyelash growth and/or reducing loss thereof
MXPA05003126A (es) Compuesto heterociclico para estimular o inducir el crecimiento del cabello o pestanas y/o frenar la perdida de cabello, c0mposicion que contiene el mismo y usos del mismo.
US20070059265A1 (en) Benzylidene-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss and/or for increasing the density of keratin fibers
ES2657376T3 (es) Composición que contiene la asociación de madecasósido y/o de terminolósido y de una arginina y/o una de sus sales y/o uno de sus derivados; utilización de la asociación para inducir y/o estimular el crecimiento de estas fibras queratínicas humanas y/o frenar su caída
WO2004069213A2 (fr) Composition de soin ou de maquillage contenant un 2-alkylideneaminooxyacetamide, utilisation de cette derniere pour stimuler la croissance des cheveux ou des cils et/ou pour ralentir leur chute
EP2448549B1 (fr) Utilisation cosmétique d'un dérivé d'acide jasmonique pour traiter les cheveux et le cuir chevelu
BRPI0900541A2 (pt) composiÇço de cuidado das fibras queratÍnicas humanas, uso cosmÉtico e processo de tratamento cosmÉtico das fibras queratÍnicas humanas e/ou do couro cabeludo
MX2007011223A (es) Composicon para el cuidado del cabello y/o las pestanas, que contiene aminexilo en combinacion con un agente para promover la produccion de oxido nitrico y usos de la misma.
US20030215409A1 (en) Process for the treatment of human keratinous fibers
WO2006079568A2 (fr) Utilisation de derives de 3-sulfanylpropanamide pour stimuler la croissance des cheveux et des cils et/ou pour arreter leur chute et/ou limiter leur depigmentation
ES2290415T3 (es) Composicion capilar que contiene un compuesto n-oxido de pirimidina, su utilizacion para estimular el crecimiento de las fibras queratinicas y/o frenar su caida.
US7326717B2 (en) Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
US8679513B2 (en) Cosmetic use of a jasmonic acid derivative for treating the hair and the scalp
WO2009077387A1 (fr) Dérivés de 2-fluoro-4-[(3,3,3-trifluoro-2-hydroxy-2-méthylpropanoyl)amino]benzoate; compositions les contenant; utilisations cosmétiques
FR2898048A1 (fr) Utilisation cosmetique d'un derive n-oxyde de theophylline
FR2825921A1 (fr) Inhibiteur de no-synthase et utilisations
FR2939435A1 (fr) Esters de l'acide 5-(phenylsulfonyl)-2-°(3,3,3-trifluoro-2- hydroxy-2-methylpropanoyl)amino!benzoique; compositions cosmetiques; utilisations pour le renforcer et/ou preserver la protection anti-oxydante naturelle de la peau
FR2808192A1 (fr) Epichatechine comme inhibiteur de no-synthase et utilisations
WO2010064203A1 (fr) Combinaison de glutathion réduit et d'acides aminés pour améliorer la qualité des cheveux de femmes
FR2939792A1 (fr) Derives de phenyl difluoroacetamide ; compositions les contenants ; utilisations cosmetiques pour renforcer et/ou preserver la protection anti-oxydante naturelle de la peau
FR2939438A1 (fr) Derives de n-(1-oxo-1,3-dihydro-2-benzofuran-5-yl) alkylamide; compositions cosmetiques; utilisations pour renforcer et/ou preserver la protection anti-oxydante naturelle de la peau

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071018

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100901